1. Home
  2. CGEM vs WGO Comparison

CGEM vs WGO Comparison

Compare CGEM & WGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.18

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Winnebago Industries Inc.

WGO

Winnebago Industries Inc.

HOLD

Current Price

$29.75

Market Cap

929.1M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
WGO
Founded
2016
1958
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
929.1M
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
CGEM
WGO
Price
$16.18
$29.75
Analyst Decision
Strong Buy
Buy
Analyst Count
8
10
Target Price
$30.13
$42.78
AVG Volume (30 Days)
778.1K
503.9K
Earning Date
05-11-2026
03-25-2026
Dividend Yield
N/A
4.40%
EPS Growth
N/A
106.82
EPS
N/A
0.36
Revenue
N/A
$1,985,674,000.00
Revenue This Year
N/A
$5.10
Revenue Next Year
$5.20
$4.69
P/E Ratio
N/A
$81.28
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$28.40
52 Week High
$16.74
$50.16

Technical Indicators

Market Signals
Indicator
CGEM
WGO
Relative Strength Index (RSI) 65.46 37.19
Support Level $11.92 $29.38
Resistance Level N/A $35.38
Average True Range (ATR) 1.02 1.09
MACD 0.27 -0.16
Stochastic Oscillator 92.55 17.39

Price Performance

Historical Comparison
CGEM
WGO

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About WGO Winnebago Industries Inc.

Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.

Share on Social Networks: